AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00309972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control arm (SEQ):
Description: Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
Study NCT00309972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental arm (CON):
Description: concurrent chemo-radiotherapy \[55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20\] followed by two cycles of cisplatinum/vinorelbine.
Study NCT00023309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine and adefovir
Description: Lamivudine (100 mg/day) and adefovir (10 mg/day)
Study NCT00023309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir alone
Description: Adefovir (10 mg/day)
Study NCT01045096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
Study NCT01045096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
Study NCT01045096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
Study NCT00708019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRO-SELF PLUS Pain Management Program
Description: The psychoeducational intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve cancer pain management. Patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. Patients in the HIGH-DOSE group will receive 6 visits and 10 phone calls \[total time 12.3 hours\]. Patients in the LOW-DOSE group will receive 4 visits and 6 phone calls \[8.0 hours\]. Follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. Both quantitative and qualitative analyses will be conducted to evaluate patient outcomes.
Study NCT03365037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electret electrostatic physiotherapyFilm
Description: Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
Study NCT03365037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fracture healing film
Description: Patients with acute soft tissue injury treated with Fracture healing film
Study NCT02381171 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active rTMS
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) 10Hz (1600 pulses)
Study NCT02381171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) 10Hz (1600 pulses)
Study NCT02381171 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) with Placebo coil
Study NCT02381171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Neuroacupuncture
Description: Neurofunctional electrical acupuncture 1Hz, continuous, 10mA current for 20 minutes.
Study NCT02381171 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active Neuroacupuncture
Description: Neurofunctional electrical acupuncture 1Hz, continuous, 10mA current for 20 minutes.
Study NCT02381171 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Neuroacupuncture
Description: Neurofunctional electrical acupuncture without needles
Study NCT01822548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: 100 mg daily
Study NCT01822548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide
Description: 2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.
Study NCT01822548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)
Study NCT01822548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)
Study NCT04500509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium + dinoprostone
Description: patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure by the patient
Study NCT04500509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diclofenac potassium + placebo
Description: patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure by the patient
Study NCT02802371 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial intervention
Description: Caregivers included in this group will benefit from a multi-component intervention with three collective sessions and individual interview in face-to-face or by phone according to the follow-up time.
Study NCT02802371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care and psychosocial support
Description: Caregivers included in this group will benefit from the same multi-component intervention that group psychosocial intervention with the integration of pharmaceutical care by a clinical pharmacist. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of the caregivers considering their medication management and the medication management of their relatives at the inclusion; 2) a collective session on medication management; and 3) personalized interviews to consider needs, medication problems and difficulties in the therapeutic optimization process.
Study NCT04330807 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Handgrip fatigability test
Description: Dynamometric and electromyographic assessment: patient is sitting on a chair, back upright, humerus vertically placed and forearm landing parallel to a support. Dominant arm is chosen for test and electrodes placement.~The assessment is divided in 4 phases for a total of 30 minutes duration: Warm-up, determination of reference force settings (fast sub-maximal contractions and maximal voluntary contractions), fatigability period and rest.
Study NCT04330807 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Assessment of subjective fatigue with Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and Multidimensional Fatigue Inventory (MFI-20) questionnaires
Study NCT01535326 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: air insufflation
Description: insufflate air during the insertion of colonoscopy
Study NCT01535326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water immersion
Description: infuse water during insertion, aspirate water during withdrawal
Study NCT01535326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water exchange
Description: infuse and remove water during insertion phase of colonoscopy
Study NCT04466085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) low-dose group
Description: Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study NCT04466085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cells) high-dose group
Description: Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study NCT04466085 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant new coronavirus vaccine (CHO cells) placebo group
Description: Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study NCT00902876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucograft
Description: Collagen Matrix for soft tissue regeneration
Study NCT00902876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Study NCT02697903 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural Pomegranate Juice
Description: Supplements (1500ml) of pomegrenate juice (POMj) were taken three times daily in the 48h which proceed the first tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Experimental: 9 elite weightlifter
Study NCT02697903 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Description: Supplements (1500ml) of Placebo juice (PLA) were taken three times daily in the 48h which proceed the second tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Placebo Comparator: 9 elite weightlifter
Study NCT03652701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair Up
Description: Herbal topical
Study NCT03652701 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04103177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chair based exercises in the dialysis environment
Description: Each participant will be given an educational / information booklet. It will include when the right time to engage in Physical Activity. The Chair-based Exercise Program will be the focus of the exercise intervention with written step- by-step instructions with demonstrative image of the exercises. Further details included in this booklet will include, information regarding the benefits of exercise including walking and safety measures in undertaking the exercises.~Sports Exercise Instructor led Chair-based Exercise Programme Patients will be given Sports Exercise Instructor led training on how to perform the chair-based exercises, for 6 weeks. This will be delivered during one of the patients' dialysis sessions. The Instructor will deliver a short 10 minute session to patients and deliver safety instruction.~Motivational interviewing Motivational interviewing will consist of discussion to encourage the participant without coercion and help them develop goals.
Study NCT03272139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Anesthetic that will help treat pain and sensation after shoulder arthroscopy
Study NCT03272139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound will help guide the anesthesiologist in performing the different nerve blocks
Study NCT01272752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHBG-10
Description: 500 mg IHBG-10
Study NCT01272752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken 15 minutes prior to the three main meals of the day
Study NCT02428699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emulsified cod liver oil product
Description: Participants are required to consume the dose (30 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
Study NCT02428699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-emulsified cod liver oil product
Description: Participants are required to consume the dose (5.8 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
Study NCT03803865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training
Description: Guided mindfulness meditation and stress management training
Study NCT03803865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reflection and Problem Solving
Description: Guided reflection,problem solving,and analytical thinking training
Study NCT00770510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 1 mg
Description: Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Study NCT00770510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 2 mg
Description: Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Study NCT00770510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Description: Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Study NCT00770510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Study NCT00770510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem Tartrate 10 mg
Description: Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Study NCT01880970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: starter infant formula with pro and prebiotics
Study NCT01880970 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Study NCT03951337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-ATSM
Description: 64 Cu-ATSM PET/CT scan
Study NCT01008657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Percutaneous multipolar radiofrequency ablation.
Study NCT01008657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Percutaneous multipolar radiofrequency ablation.
Study NCT03987009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Without RAMP and without video
Description: Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning without RAMP device
Study NCT03987009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With RAMP and with video
Description: Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning with RAMP device
Study NCT03987009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Without RAMP and with video
Description: Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning without RAMP device
Study NCT03987009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With RAMP and without video
Description: Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning with RAMP device
Study NCT02673580 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Open Access telePRO
Description: In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website Sundhed.dk.
Study NCT02673580 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard telePRO
Description: Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
Study NCT02747615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transfused pre-operatively donated autologous blood.
Description: Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion
Study NCT02747615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous tranexamic acid (TXA) infusion
Description: Intravenous tranexamic acid is a safe pharmacological treatment to reduce blood loss and transfusion requirements in patients undergoing major orthopedic surgery.
Study NCT02747615 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: transfused only allogeneic blood.
Study NCT01949194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: The dose of regorafenib given will be 160 mg once a day (od) oral (po), using a 21 days on / 7 days off treatment schedule. This equates to four (4) tablets once a day for three (3) weeks. The patient should take the dose at the same time each day, with a full glass of water, and following a light meal. A light mealconsists of less than 30% fat and around 300-550 calories.
Study NCT03816371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head-of-bed elevation
Description: Respiratory pattern including respiratory rate, peripheral oxygen saturation and dyspnea, and drainage including amount of drainage and hematoma formation of all patients were evaluated at 1st, 2nd, 3rd, and 4th hours after positions.
Study NCT03816371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head-of-bed elevation
Description: Respiratory pattern including respiratory rate, peripheral oxygen saturation and dyspnea, and drainage including amount of drainage and hematoma formation of all patients were evaluated at 1st, 2nd, 3rd, and 4th hours after positions.
Study NCT03637582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine gel
Description: Lidocaine (4%) gel from Quest Products, Inc.
Study NCT03637582 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain aqueous gel
Description: KY jelly lubricant from Reckitt Benckiser
Study NCT03365375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR Referral
Description: Referral for mindfulness-based stress reduction (MBSR), a structured meditation training program consisting of 8 weekly group sessions.
Study NCT03365375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care Referral
Description: Referral to PCP or Psychiatry
Study NCT03365375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Referral
Description: Referral to PCP or Psychiatry
Study NCT04095871 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: No intervention, patients record the time of CISC
Study NCT04200482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Diet and Physical Activity Session
Description: Attend 1 remote diet and physical activity session
Study NCT04200482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic (e) Health (eHealth) Communication Intervention
Description: Receive eHealth communication intervention
Study NCT04200482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic (e) Health (eHealth) Communication Intervention
Description: Receive eHealth communication intervention
Study NCT04200482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twelve Diet and Physical Activity Group Sessions
Description: Attend 12 remote diet and physical activity sessions in 6 months
Study NCT04200482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04200482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04200482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04200482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01931033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Study NCT03788525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced recreational screen time
Description: Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use this device for necessary contact. The families are allowed a maximum of 3 hours/week of recreational screen time. If participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.